CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Panitumumab +2 moredrug
Likely dose
Panitumumab 6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01308840
NCT01308840Phase 2Completed
CompareCT.gov

Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer

University of Rochester·interventional·Posted Mar 4, 2011·Updated Aug 17, 2016

In Brief

A Phase 2 clinical trial evaluating Panitumumab, oxaliplatin, and 1 other intervention for Biliary Tract Cancer and Gallbladder Cancer. Completed, enrolled 31 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine disease response of GEMOX-Panitumumab (GEMOX-P) in KRAS/ BRAF wild-type, Stage IV, biliary tract and gallbladder cancer patients who have previously not received chemotherapy. This study will also examine the potential toxicities, progression-free and overall survival in this population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Tract Cancer, Gallbladder Cancer
CountriesUnited States
CollaboratorsAmgen

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 4, 2011
Enrollment StartDec 1, 2010
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.3 years ago

Interventions

Panitumumabdrug

Day 1 and 15 = 6 mg/kg IV

oxaliplatindrug

Days 1 and 15 = 85mg/m2 IV

gemcitabinedrug

Days 1 and 15 = 1000 mg/m2 IV